Latest News for: nrg1

Edit

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented ...

News Graphic 07 Dec 2025
LEXINGTON, Mass., Dec.
Edit

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

PR Newswire 06 Dec 2025
The new analysis evaluated the efficacy and safety of zenocutuzumab-zbco in treatment-naïve and previously treated NRG1+ NSCLC ... About NRG1 Gene Fusions ... NRG1 Gene Fusion Positive Unresectable or Metastatic NSCLC.
Edit

Rare NRG1 Fusion Market Research Report 2025-2035 Featuring Merus, Hummingbird Bioscience, Elevation Oncology (Concentra Biosciences), ...

Business Wire 25 Nov 2025
DUBLIN--(BUSINESS WIRE)--The "Rare NRG1 Fusion Market - A Global and Regional Analysis.
Edit

Rare NRG1 Fusion Market Research Report 2025-2035 | Growth Accelerates on Rising Cancer Awareness and ...

Nasdaq Globe Newswire 24 Nov 2025
The global rare NRG1 fusion market is set for significant growth from 2024 to 2035, driven by increased awareness of NRG1 fusions linked to cancers like pancreatic and non-small cell lung cancers.
Edit

Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in ...

Williston Observer 24 Oct 2025
Investigational treatment with zenocutuzumab-zbco in adults with advanced unresectable or metastatic NRG1+ cholangiocarcinoma showed a 37% ORR, median time to response of 1.9 months, and median duration of response of 7.4 months ....
Edit

Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC

PR Newswire 23 Oct 2025
Investigational treatment with zenocutuzumab-zbco in adults with advanced unresectable or metastatic NRG1+ cholangiocarcinoma showed a 37% ORR, median time to response of 1.9 months, and median duration of response of 7.4 months.
  • 1

Article Search

tools
×
×
×
×